Patents by Inventor William M. Mackin

William M. Mackin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Assay for binding between carbohydrate and glycolipid
    Patent number: 6630310
    Abstract: A preparation containing a receptor for underivatized, aqueous soluble &bgr;(1-3)-glucan is disclosed, along with characterization of the receptor for underivatized, aqueous soluble &bgr;(1-3)-glucan. Also described are assays for identifying agents which alter the effect of underivatized, aqueous soluble &bgr;(1-3)-glucan on activation of signal transduction pathways and agents identified thereby, as well as assays for assessing the specificity of carbohydrate:glycolipid interactions.
    Type: Grant
    Filed: October 30, 1998
    Date of Patent: October 7, 2003
    Assignee: Biopolymer Engineering Pharmaceutical, Inc.
    Inventors: Eric Wakshull, William M. Mackin, Janet Zimmerman
  • &bgr;(1-3)-glucan diagnostic assays
    Patent number: 6413715
    Abstract: Methods of isolating &bgr;(1-3)-glucan or &bgr;(1-3)-glucan-containing organisms in a sample, or of detecting the presence of &bgr;(1-3)-glucan or &bgr;(1-3)-glucan-containing organisms in a sample, utilizing binding agents for &bgr;(1-3)-glucan, such as LacCer, GalCer, globotriaosylceramide and asialoganglioside-GM1, are described. Methods of diagnosing fungal infection, by detecting &bgr;(1-3)-glucan or &bgr;(1-3)-glucan-containing organisms, are also described. Antibodies and kits useful in the methods are also disclosed.
    Type: Grant
    Filed: June 19, 2001
    Date of Patent: July 2, 2002
    Assignee: The Collaborative Group
    Inventors: Eric M. Wakshull, William M. Mackin, Janet W. Zimmerman, Leslie W. Fisette
  • Beta (1-3) -glucan diagnostic assays
    Publication number: 20010051717
    Abstract: Methods of isolating &bgr;(1-3)-glucan or &bgr;(1-3)-glucan-containing organisms in a sample, or of detecting the presence of &bgr;(1-3)-glucan or &bgr;(1-3)-glucan-containing organisms in a sample, utilizing binding agents for &bgr;(1-3)-glucan, such as LacCer, GalCer, globotriaosylceramide and asialoganglioside-GM1, are described. Methods of diagnosing fungal infection, by detecting &bgr;(1-3)-glucan or &bgr;(1-3)-glucan-containing organisms, are also described. Antibodies and kits useful in the methods are also disclosed.
    Type: Application
    Filed: June 19, 2001
    Publication date: December 13, 2001
    Applicant: Collaborative Group, Ltd.
    Inventors: Eric M. Wakshull, William M. Mackin, Janet W. Zimmerman, Leslie W. Fisette
  • &bgr;(1-3)-glucan diagnostic assays
    Patent number: 6294321
    Abstract: Methods of isolating &bgr;(1-3)-glucan or &bgr;(1-3)-glucan-containing organisms in a sample, or of detecting the presence of &bgr;(1-3)-glucan or &bgr;(1-3)-glucan-containing organisms in a sample, utilizing binding agents for &bgr;(1-3)-glucan, such as LacCer, GalCer, globotriaosylceramide and asialoganglioside-GM1, are described. Methods of diagnosing fungal infection, by detecting &bgr;(1-3)-glucan or &bgr;(1-3)-glucan-containing organisms, are also described. Antibodies and kits useful in the methods are also disclosed.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: September 25, 2001
    Assignee: The Collaborative Group
    Inventors: Eric M. Wakshull, William M. Mackin, Janet W. Zimmerman, Leslie W. Fisette
  • Receptor for underivatized aqueous soluble .beta.(1-3)-glucan
    Patent number: 6110692
    Abstract: A preparation containing a receptor for underivatized, aqueous soluble .beta.(1-3)-glucan is disclosed, along with characterization of the receptor for underivatized, aqueous soluble .beta.(1-3)-glucan. Also described are assays for identifying agents which alter the effect of underivatized, aqueous soluble .beta.(1-3)-glucan on activation of signal transduction pathways and agents identified thereby.
    Type: Grant
    Filed: January 31, 1997
    Date of Patent: August 29, 2000
    Assignee: The Collaborative Group, Ltd.
    Inventors: Eric Wakshull, William M. Mackin, Janet Zimmerman
  • Activation of signal transduction by underivatized, aqueous soluble . .beta(1-3)-Glucan
    Patent number: 6090938
    Abstract: A preparation containing a receptor for underivatized, aqueous soluble .beta.(1-3)-glucan is disclosed, along with characterization of the receptor for underivatized, aqueous soluble .beta.(1-3)-glucan. Also described are assays for identifying agents which alter the effect of underivatized, aqueous soluble .beta.(1-3)-glucan on activation of signal transduction pathways and agents identified thereby.
    Type: Grant
    Filed: June 14, 1996
    Date of Patent: July 18, 2000
    Assignee: Collaborative Group, Ltd.
    Inventors: Eric Wakshull, William M. Mackin, Janet Zimmerman
  • .beta.(1-3)-glucan diagnostic assays
    Patent number: 6084092
    Abstract: Methods of isolating .beta.(1-3)-glucan or .beta.(1-3)glucan-containing organisms in a sample, or of detecting the presence of .beta.(1-3)-glucan or .beta.(1-3)-glucan-containing organisms in a sample, utilizing binding agents for .beta.(1-3)-glucan, such as LacCer, GalCer, globotriaosylceramide and asialoganglioside-GM1, are described. Methods of diagnosing fungal infection, by detecting .beta.(1-3)-glucan or .beta.(1-3)-glucan-containing organisms, are also described. Antibodies and kits useful in the methods are also disclosed.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: July 4, 2000
    Assignee: The Collaborative Group, Ltd.
    Inventors: Eric M. Wakshull, William M. Mackin, Janet W. Zimmerman, Leslie W. Fisette
  • Azapropazone prevention of post-ischemic tissue damage
    Patent number: 4668676
    Abstract: Azapropazone can be used to prevent post-ischemic tissue damage in mammals.
    Type: Grant
    Filed: July 15, 1986
    Date of Patent: May 26, 1987
    Assignee: E.I. Du Pont de Nemours and Company
    Inventors: George A. Boswell, William M. Mackin, Martin J. Thoolen